Not necessarily.
The leading clinical model of women's desire describes it as often responsive, arising during an experience begun for other reasons, rather than spontaneous, and the absence of spontaneous desire on its own is not considered a dysfunction. A proper evaluation for low desire is meant to be biopsychosocial, meaning it should look at relationship factors, mental health, medications (SSRIs in particular), body image, stress and sleep before or alongside any biological treatment. There are two FDA-approved non-hormonal medications for low desire in premenopausal women, but an independent review of one of them found only a modest average benefit, about half an additional satisfying sexual event per month, alongside real side effects, and rated the overall evidence quality very low. What actually matters diagnostically is whether the low desire is causing you distress, not simply whether the frequency is lower than it used to be.
There is a real tension between framing low desire as something a pill can fix versus a biopsychosocial issue requiring broader evaluation; the independent trial data land closer to the second view, even though the medications remain real, if modest, tools once other factors are addressed.
What the research shows, and which source each finding rests on
The dominant clinical model of women's desire describes it as often responsive, arising during a sexual experience begun for other reasons, rather than spontaneous; absence of spontaneous desire is not by itself dysfunction.
Low desire is formally a biopsychosocial diagnosis; the ISSWSH guideline requires assessing modifiable factors, relationship, mental health, medications (notably SSRIs), body image, stress and sleep, before and alongside any biological treatment.
Two FDA-approved non-hormonal drugs exist for HSDD in premenopausal women, flibanserin and bremelanotide; an independent meta-analysis of flibanserin (8 studies, 5,914 women) found on average about one-half additional satisfying sexual event per month, with significantly increased dizziness, somnolence, nausea and fatigue, and rated overall evidence quality 'very low.'
Where the real disagreement is
Each position is shown with its own sources. A position listed here is not necessarily the accepted view.
Low desire deserves a biopsychosocial workup first
Kelly Casperson, MD; ISSWSH guideline
Responsive desire is normal physiology, not dysfunction, and painful sex causing avoidance is not itself a desire disorder, it's untreated GSM being misread as low libido; scheduling sex is meant to create conditions for desire, never an obligation.
Medication has a real, if modest, role after workup
Kelly Casperson, MD, on real-world prescribing
In practice, flibanserin and bremelanotide are niche but real tools after a full biopsychosocial evaluation, even though the independent meta-analysis found the average benefit modest and the evidence quality low.
What would settle it: Higher-quality, longer trials of both medications with clearer distress-based endpoints, alongside more research on responsive-desire-based counseling approaches, would clarify how much of low desire responds to a biological versus relational or contextual intervention.
What is really going on here
- Before testosterone or medication: has anyone assessed my relationship, mood, medications, sleep, and whether sex hurts?
Questions for your doctor
- Could my medications, especially an SSRI, be contributing to this?
- Is sex painful, and could that be driving avoidance rather than true low desire?
- Should we look at relationship, stress or sleep factors before considering medication?
- If we do consider a medication, what benefit and side effects should I realistically expect?
Questions with no answer yet
Is there a way to test in advance whether a particular woman's low desire is more likely to respond to a biopsychosocial approach, such as relationship, mood, sleep, or medication changes, versus a medication, rather than trying one after the other?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: The guideline requires assessing modifiable factors before or alongside any biological treatment, without a validated screening tool that predicts which category of intervention, behavioral, relational, or pharmacologic, is more likely to help a given woman.
What would test it: A study developing and validating a predictive screening tool that matches women to the intervention type most likely to help them, tested against actual outcomes.
Given that an independent review of one approved medication rated the overall evidence quality very low despite finding a statistically real average benefit, would a longer or larger trial change that quality rating, or is 'very low quality but real effect' likely to be the permanent verdict for this drug?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: The independent meta-analysis found a real, if modest, average benefit, about half an additional satisfying sexual event per month, alongside meaningful side effects, and explicitly rated overall evidence quality as very low, without a subsequent larger or longer trial reported that would upgrade that quality assessment.
What would test it: A larger, longer, and more rigorously designed trial of the same medication, specifically built to address the quality concerns the independent review raised.
Does painful sex that has never been properly diagnosed get mislabeled as low desire more often than currently recognized, and if so, how many women prescribed a desire medication actually needed genitourinary treatment instead?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: Painful sex causing avoidance is described as not itself a desire disorder but untreated genitourinary syndrome being misread as low libido, framed as a critical question worth asking, without a study quantifying how often this misattribution actually happens in real-world prescribing.
What would test it: A study auditing women prescribed a desire medication to see what proportion had unaddressed painful sex or other genitourinary symptoms at the time of prescribing.
Sources
- 1.The female sexual response: a different model.Basson R. The female sexual response: a different model. J Sex Marital Ther 2000;26(1):51-65 · Review, opinion or mechanism
- 2.International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women.Parish SJ, Simon JA, Davis SR, et al. ISSWSH Clinical Practice Guideline for the Use of Systemic Testosterone for HSDD in Women. J Sex Med 2021;18(5):849-867 · Systematic review or guideline
- 3.Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women: A Systematic Review and Meta-analysis.Jaspers L, et al. Efficacy and Safety of Flibanserin for HSDD in Women: A Systematic Review and Meta-analysis. JAMA Intern Med 2016;176(4):453-62 · Systematic review or guideline
The letter grades the type of study behind a claim, not the answer itself.
This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.
You are not imagining it
In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.
Start Free MappingRelated questions
- What is GSM (genitourinary syndrome of menopause) and why does it affect both my vagina and my bladder?
- Is vaginal estrogen safe, and what happened to that scary warning label about stroke and cancer?
- Can I use vaginal estrogen if I've had breast cancer?
- I keep getting UTIs after menopause and keep getting put on antibiotics - can vaginal estrogen actually help?
- Sex has become painful since perimenopause - is this just something I have to live with?
- What is vaginal DHEA (prasterone) and how is it different from vaginal estrogen?
- Back to topic: Vaginal, sexual and urinary health